2026-2034年全球肿瘤伴随诊断测试市场规模、份额、趋势和成长分析报告

预计肿瘤伴随诊断测试的市场规模将从 2025 年的 80.2 亿美元成长到 2034 年的 189.3 亿美元，2026 年至 2034 年的复合年增长率为 10.01%。

随着个人化医疗在癌症治疗中的重要性日益凸显，肿瘤领域伴随诊断检测的全球市场正在迅速扩张。伴随诊断检测能够帮助判断患者是否可能从特定的癌症治疗中获益。这些检测透过分析肿瘤的​​基因突变、生物标记和其他分子特征，为治疗决策提供支持。

全球癌症发生率的上升和标靶治疗的日益普及是推动市场成长的主要因素。製药公司和诊断设备製造商正携手合作，在研发新药的同时开发伴随诊断测试。分子诊断和基因测序技术的进步也提高了这些测试的准确性和可靠性。

未来，随着精准癌症治疗的进步，市场预计将显着成长。随着癌症基因组研究和生物标记发现研究的活性化，新型诊断工具的开发也将持续推进。随着医疗机构致力于提供个人化癌症治疗，伴随诊断测试将在改善治疗效果方面发挥至关重要的作用。

目录

第一章：引言

第二章执行摘要

第三章 市场变数、趋势与框架

• 市场谱系展望
• 渗透率和成长前景分析
• 价值链分析
• 法律规范
  • 标准与合规性
  • 监管影响分析
• 市场动态
  • 市场驱动因素
  • 市场限制因素
  • 市场机会
  • 市场挑战
• 波特五力分析
• PESTLE分析

第四章：全球肿瘤伴随诊断检验市场：依检测技术划分

• 市场分析、洞察与预测
• 蛋白质检测
• DNA检测
• 其他的

第五章 全球肿瘤领域伴随诊断检验市场：依生物标记划分

• 市场分析、洞察与预测
• EGFR
• KRAS
• HER2
• BRAF V600E
• 其他的

第六章 全球肿瘤伴随诊断测试市场：依癌症类型划分

• 市场分析、洞察与预测
• 乳癌
• 肺癌
• 结肠癌
• 肝癌
• 黑色素瘤
• 其他的

第七章 全球肿瘤领域伴随诊断测试市场：依最终用户划分

• 市场分析、洞察与预测
• 医院
• 专科诊所
• 诊断检查室
• 其他的

第八章 全球肿瘤伴随诊断测试市场：按地区划分

• 区域分析
• 北美市场分析、洞察与预测
  • 我们
  • 加拿大
  • 墨西哥
• 欧洲市场分析、洞察与预测
  • 英国
  • 法国
  • 德国
  • 义大利
  • 俄罗斯
  • 其他欧洲国家
• 亚太市场分析、洞察与预测
  • 印度
  • 日本
  • 韩国
  • 澳洲
  • 东南亚
  • 其他亚太国家
• 拉丁美洲市场分析、洞察与预测
  • 巴西
  • 阿根廷
  • 秘鲁
  • 智利
  • 其他拉丁美洲国家
• 中东和非洲市场分析、洞察与预测
  • 沙乌地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中东和非洲国家

第九章 竞争情势

• 最新趋势
• 公司分类
• 供应链和销售管道合作伙伴（根据现有资讯）
• 市场占有率和市场定位分析（基于现有资讯）
• 供应商情况（基于现有资讯）
• 策略规划

第十章：公司简介

• 主要公司的市占率分析
• 公司简介
  • Abbott Laboratories
  • F. Hoffmann-La Roche Ltd
  • Genomic Health Inc
  • Qiagen NV
  • Agilent Technologies Inc
  • Agendia NV
  • BioMAfA（C）Rieux SA
  • Illumina Inc
  • Siemens Healthineers AG
  • Thermo Fisher Scientific Inc
  • BioGenex Laboratories Inc

The Companion Diagnostic Tests in Oncology Market size is expected to reach USD 18.93 Billion in 2034 from USD 8.02 Billion (2025) growing at a CAGR of 10.01% during 2026-2034.

The global companion diagnostic tests in oncology market is expanding rapidly as personalized medicine becomes more important in cancer treatment. Companion diagnostics are tests that help determine whether a patient is likely to benefit from a specific cancer therapy. These tests analyze genetic mutations, biomarkers, or other molecular characteristics of tumors to guide treatment decisions.

The increasing prevalence of cancer worldwide and the growing adoption of targeted therapies are major drivers of market growth. Pharmaceutical companies and diagnostic manufacturers are collaborating to develop companion diagnostic tests alongside new cancer drugs. Advances in molecular diagnostics and genomic sequencing technologies are also improving the accuracy and reliability of these tests.

Looking ahead, the market is expected to grow significantly as precision oncology continues to evolve. Increasing research in cancer genomics and biomarker discovery will lead to the development of new diagnostic tools. As healthcare providers focus on delivering personalized cancer treatments, companion diagnostic testing will play an essential role in improving treatment outcomes.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Detection Technique

• Protein Detection
• DNA Detection
• Others

By Biomarker

• EGFR
• KRAS
• HER2
• BRAF V600E
• Others

By Cancer Type

• Breast Cancer
• Lung Cancer
• Colorectal Cancer
• Liver Cancer
• Melanoma
• Others

By End-user

• Hospitals
• Specialty Clinics
• Diagnostic Labs
• Others

COMPANIES PROFILED

• Abbott Laboratories, F HoffmannLa Roche Ltd, Genomic Health Inc, Qiagen NV, Agilent Technologies Inc, Agendia NV, bioMrieux SA, Illumina Inc, Siemens Healthineers AG, Thermo Fisher Scientific Inc, BioGenex Laboratories Inc
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL COMPANION DIAGNOSTIC TESTS IN ONCOLOGY MARKET: BY DETECTION TECHNIQUE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Detection Technique
• 4.2. Protein Detection Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. DNA Detection Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL COMPANION DIAGNOSTIC TESTS IN ONCOLOGY MARKET: BY BIOMARKER 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Biomarker
• 5.2. EGFR Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. KRAS Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. HER2 Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. BRAF V600E Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.6. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL COMPANION DIAGNOSTIC TESTS IN ONCOLOGY MARKET: BY CANCER TYPE 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Cancer Type
• 6.2. Breast Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Lung Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Colorectal Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.5. Liver Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.6. Melanoma Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.7. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL COMPANION DIAGNOSTIC TESTS IN ONCOLOGY MARKET: BY END-USER 2022-2034 (USD MN)

• 7.1. Market Analysis, Insights and Forecast End-user
• 7.2. Hospitals Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.3. Specialty Clinics Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.4. Diagnostic Labs Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL COMPANION DIAGNOSTIC TESTS IN ONCOLOGY MARKET: BY REGION 2022-2034(USD MN)

• 8.1. Regional Outlook
• 8.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.2.1 By Detection Technique
  • 8.2.2 By Biomarker
  • 8.2.3 By Cancer Type
  • 8.2.4 By End-user
  • 8.2.5 United States
  • 8.2.6 Canada
  • 8.2.7 Mexico
• 8.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.3.1 By Detection Technique
  • 8.3.2 By Biomarker
  • 8.3.3 By Cancer Type
  • 8.3.4 By End-user
  • 8.3.5 United Kingdom
  • 8.3.6 France
  • 8.3.7 Germany
  • 8.3.8 Italy
  • 8.3.9 Russia
  • 8.3.10 Rest Of Europe
• 8.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.4.1 By Detection Technique
  • 8.4.2 By Biomarker
  • 8.4.3 By Cancer Type
  • 8.4.4 By End-user
  • 8.4.5 India
  • 8.4.6 Japan
  • 8.4.7 South Korea
  • 8.4.8 Australia
  • 8.4.9 South East Asia
  • 8.4.10 Rest Of Asia Pacific
• 8.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.5.1 By Detection Technique
  • 8.5.2 By Biomarker
  • 8.5.3 By Cancer Type
  • 8.5.4 By End-user
  • 8.5.5 Brazil
  • 8.5.6 Argentina
  • 8.5.7 Peru
  • 8.5.8 Chile
  • 8.5.9 South East Asia
  • 8.5.10 Rest of Latin America
• 8.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.6.1 By Detection Technique
  • 8.6.2 By Biomarker
  • 8.6.3 By Cancer Type
  • 8.6.4 By End-user
  • 8.6.5 Saudi Arabia
  • 8.6.6 UAE
  • 8.6.7 Israel
  • 8.6.8 South Africa
  • 8.6.9 Rest of the Middle East And Africa

Chapter 9. COMPETITIVE LANDSCAPE

• 9.1. Recent Developments
• 9.2. Company Categorization
• 9.3. Supply Chain & Channel Partners (based on availability)
• 9.4. Market Share & Positioning Analysis (based on availability)
• 9.5. Vendor Landscape (based on availability)
• 9.6. Strategy Mapping

Chapter 10. COMPANY PROFILES OF GLOBAL COMPANION DIAGNOSTIC TESTS IN ONCOLOGY INDUSTRY

• 10.1. Top Companies Market Share Analysis
• 10.2. Company Profiles
  • 10.2.1 Abbott Laboratories
  • 10.2.2 F. Hoffmann-La Roche Ltd
  • 10.2.3 Genomic Health Inc
  • 10.2.4 Qiagen N.V
  • 10.2.5 Agilent Technologies Inc
  • 10.2.6 Agendia N.V
  • 10.2.7 BioMAfA(C)Rieux SA
  • 10.2.8 Illumina Inc
  • 10.2.9 Siemens Healthineers AG
  • 10.2.10 Thermo Fisher Scientific Inc
  • 10.2.11 BioGenex Laboratories Inc